Alchemab is a Cambridge biotech that aims to revolutionise drug discovery with a novel alternative to big pharma’s classic “choose a target” approach. Optimum’s Richard Staines caught up with Alchemab’s CEO, Young Kwon, to find out more. The UK has long been a leader in the field of antibody drug technology, and it was British […]
Optimum Strategic Communications sends our heartfelt congratulations to Jane Osbourn OBE, the co-founder and chief scientific officer of Alchemab, who was presented with a Lifetime Achievement Award by the BioIndustry Association last night, in recognition of her achievements as a leading figure in UK life science. Before founding Alchemab, Jane served as vice president at […]
THE CHAIN PODCAST Our Co-Founder and CSO Jane Osbourn was delighted to speak with her longtime friend Ahuva Nissim, antibody and therapeutic engineering professor at William Harvey Research Institute, Queen Mary University of London, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with convergent […]
Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor Conference and wow, what a fantastic event it was! After two years of disruption, we were delighted to be meeting again in person. While virtual meetings have been a fantastic boon during these difficult times, nothing can beat meeting and sharing ideas and opinions face-to-face, […]
